These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11139674)

  • 1. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
    Loubière S; Rotily M; Moatti JP
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of the treatment of chronic hepatitis C].
    Joliot E; Vanlemmens C; Kerleau M; Le Gales C; Woronoff-Lemsi MC; Flori YA; Seror V; Hrusovsky S; Monnet E; Bresson-Hadni S; Miguet JP
    Gastroenterol Clin Biol; 1996; 20(11):958-67. PubMed ID: 9119185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha].
    Buti M; Casado MA; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 1998 Apr; 21(4):161-8. PubMed ID: 9633175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
    Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Compared efficiency of three strategies of management of chronic hepatitis C. Effect on the risk of cirrhosis 8 years after diagnosis].
    Michel P; Merle V; Gourier C; Hochain P; Colin R; Czernichow P
    Gastroenterol Clin Biol; 1996 Feb; 20(1):47-54. PubMed ID: 8734312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C therapy: is it really worth it?
    Johanson JF
    Am J Gastroenterol; 1999 May; 94(5):1412-3. PubMed ID: 10235231
    [No Abstract]   [Full Text] [Related]  

  • 8. Economics of chronic hepatitis B and hepatitis C.
    Rajendra A; Wong JB
    J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of interferon in chronic active hepatitis C.
    Turnbull C; Sugano D
    Med J Aust; 1994 Jul; 161(2):169; author reply 170. PubMed ID: 8028544
    [No Abstract]   [Full Text] [Related]  

  • 10. Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
    Veldt BJ; Hansen BE; Eijkemans MJ; de Knegt RJ; Stijnen T; Habbema JD; Schalm SW
    Aliment Pharmacol Ther; 2005 Mar; 21(5):539-47. PubMed ID: 15740537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA; Lacey LF; Payne SL; Miller DW
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Babu S
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929872
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Desai HG
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929870
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy of hepatitis C: cost-effectiveness analysis.
    Koff RS
    Hepatology; 1997 Sep; 26(3 Suppl 1):152S-155S. PubMed ID: 9305681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
    Aggarwal R; Ghoshal UC; Naik SR
    Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C.
    Shiell A; Briggs A; Farrell GC
    Med J Aust; 1994 Mar; 160(5):268-72. PubMed ID: 8107627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Nagral A
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929871
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience.
    Pojoga C; Dumitraşcu DL; Pascu O; Grigorescu M
    J Gastrointestin Liver Dis; 2006 Mar; 15(1):31-5. PubMed ID: 16680230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost evaluation of therapeutic management of patients with chronic hepatitis C].
    Faure C; Gasser P; Douet MC
    Therapie; 1997; 52(6):553-8. PubMed ID: 9734107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.